期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌综合治疗的发展和现状 被引量：8

原文传递
导出
摘要 乳腺癌是全世界女性最常见的恶性肿瘤，在我国乳腺癌发病率也居女性恶性肿瘤之首，且仍在快速增长。然而，随着乳腺癌防治水平的提高，其死亡率有所下降，这主要归功于乳腺癌综合治疗的发展（图1），包括手术治疗、化学治疗、放射治疗、内分泌治疗和分子靶向治疗等治疗策略。本文综述了乳腺癌综合治疗的发展和现状。
作者 杨芳 王林伟 袁静萍 李雁
机构地区 武汉大学中南医院肿瘤科/肿瘤生物学行为湖北省重点实验室/湖北省肿瘤医学临床研究中心
出处 《医学新知》 CAS 2015年第2期111-114,共4页 New Medicine
基金 国家自然科学基金重点项目（81230031/H18）,湖北省医学领军人才培养工程计划（2013[4]）,国家自然科学基金项目（61272274）
关键词 乳腺癌 手术 化疗 放疗 内分泌治疗 分子靶向治疗
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Black D M, Hunt K K, Mittendorf E A. Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy :20 - year results of EORTC 10801 [ J ]. Gland Surg, 2013,2 ( 3 ) : 120- 123.
  • 2Zhang B,Song Q,Zhang B,et al. A 10 - year( 1999 - 2008) retro- spective multi - center study of breast cancer surgical management in various geographic areas of China [ J ]. Breast, 2013,22 ( 5 ) : 676- 681.
  • 3Yueh J H, Slavin S A, Adesiyun T, ct al. Patient satisfaction in post- mastectomy breast reconstruction:a comparative evaluation of DIEP, TRAM,latissimus flap, and implant techniques [ J]. Plast Reconstr Surg ,2010,125 ( 6 ) : 1585-1595.
  • 4Krag D N, Anderson S J, Julian T B, et al. Sentinel - lymph - node resection compared with conventional axillary - lymph - node dissec- tion in clinically node -negative patients with breast cancer: overall survival findings from the NSABP B - 32 randomised phase 3 trial [ J ]. Lancet Oncol,2010,11 (10) :927-933.
  • 5Moncayo V M, Aarsvold J N, Grant S F, et al. Status of sentinel lymph node for breast cancer[J]. Semin Nucl Med,2013,43(4) :281-293.
  • 6Luo C, Guo W, Yang J, et al. Comparison of mastoscopic and conven- tional axillary lymph node dissection in breast cancer:long- term re-suits from a randomized, multicenter trial [ J ]. Mayo Clin Proc,2012, 87(12) :1153-1 161.
  • 7Hutchins L F. Randomized, controlled trial of cyelophosphamide, methotrexate, and fluorouraeil versus cyclophosphamide, doxorubi- cin, and fluomuracil with and without tamoxifen for high - risk, node - negative breast cancer:treatment results of intergroup protocol INT - 0102 [ J ]. Journal of Clinical Oncology, 2005,23 ( 33 ) : 8313- 8321.
  • 8Coudert B, Asselain B, Campone M, et al. Extended benefit from se- quential administration of docetaxel after standard fluorouracil, epiru- bicin, and cyclophosphamide regimen for node -positive breast canc- er:the 8 - year follow - up results of the UNICANCER - PACS01 tri- M [ J ]. The Oncologist,2012,17 (7) :900-909.
  • 9Seidman A D, Berry D, Cirrincione C, et al. Randomized phase llI tri- M of weekly compared with every - 3 - weeks paclitaxel for metastatic breast cancer,with trastuzumab for all HER -2 overexpressors and random assignment to trastuzumab or not in HER -2 nonoverexpres- sors : final results of cancer and leukemia group B protocol 9840 [ J ]. J Clin Oncol,2008,26(10) :1642-1649.
  • 10Teshome M, Hunt K K. Neoadjuvant therapy in the treatment of breast cancer[ J]. Surg Oncol Clin N Am,2014,23 (3) :505 - 523.

二级参考文献5

共引文献6

同被引文献104

  • 1冯正权,倪克锋,何煜,丁志山,朱峰,吴良村,沈敏鹤.三叶青黄酮诱导SGC-7901胃癌细胞凋亡的实验研究[J].中国临床药理学与治疗学,2006,11(6):669-672. 被引量：77
  • 2冯志英,王建荣,张黎明,马燕兰,魏畅,郭俊艳.住院患者护理工作满意度量表的研制[J].中华护理杂志,2007,42(1):63-66. 被引量：326
  • 3Lu WL, Li HX, Qian BY, et al. The Clinical Characteristics and Prognosis of Chinese Early Stage Breast Cancer Patients: A Retrospective Study[J]. Breast Journal, 2010, 16(3):331-333.
  • 4Bruno C, Bernard A, Mario C, et al. Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial[J]. Oncologist, 2012, 17(7):900-909.
  • 5Teshome M, Hunt KK. Neoadjuvant Therapy in the Treatment of Breast Cancer[J]. Surgical Oncology Clinics of North America, 2014, 23(3):505-523.
  • 6Rudat V, Alaradi AA, Mohamed A, et al. Tangential beam IMRT versus tangential beam 3D-CRT of the chest wall in postmastectomy breast cancer patients: a dosimetric comparison[J]. Radiation Oncology, 2011, 6(1):23-30.
  • 7Chia SK, Ac. W. With maturity comes confidence: EBCTCG tamoxifen update[J]. Lancet, 2011, 378(9793):747-749.
  • 8Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up[J]. Lancet Oncology, 2011, 12(12):1101-1108.
  • 9Ellis MJ. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype ACOSOG Z1031[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2011, 29(17): 2342-2349.
  • 10Schneeweiss A. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)[J]. Annals of Oncology, 2013, 24(9):2278-2284.

引证文献8

二级引证文献42

医学新知
2015年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部